Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | GSK3B | P49841 | 3/20 | 0.51 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | THRA | P10827 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8610840 | 0.91 | MAPK1 (0.54) | CYP4F2CYP4A11MAPTL3MBTL1LMNA | |
| SCHEMBL14028452 | 0.86 | CYP4F2 (0.66) | CYP4F2CYP4A11MAPTL3MBTL1LMNA | |
| SCHEMBL68902 | 0.85 | CYP4F2 (0.85) | CYP4F2CYP4A11MAPTL3MBTL1LMNA | |
| SCHEMBL5913041 | 0.84 | CYP4F2 (0.64) | CYP4F2CYP4A11MAPTL3MBTL1LMNA | |
| SCHEMBL392939 | 0.84 | GSK3B (0.55) | MAPTLMNAGSK3BCYP4Z1ALDH1A1 | |
| SCHEMBL168856 | 0.84 | GSK3B (0.54) | CYP4F2CYP4A11MAPTL3MBTL1LMNA | |
| SCHEMBL4887611 | 0.83 | CYP4F2 (0.72) | CYP4F2CYP4A11MAPTL3MBTL1LMNA | |
| SCHEMBL6781618 | 0.83 | CYP4F2 (0.72) | CYP4F2CYP4A11MAPTL3MBTL1LMNA | |
| SCHEMBL20734882 | 0.83 | CYP4F2 (0.62) | CYP4F2CYP4A11MAPTL3MBTL1LMNA | |
| SCHEMBL7766764 | 0.82 | CYP4F2 (0.70) | CYP4F2CYP4A11MAPTL3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1786792-B1 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC (JP) | 2009-04-08 | — | — | EP | disclosed |
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | ASTELLAS PHARMA INC. (JP) | 2007-11-01 | — | — | US | disclosed |
| CN-101031555-A | Thiazole derivative capable of vap-1 inhibitory activity | ASTELLAS PHARMA INC (JP) | 2007-09-05 | — | — | CN | disclosed |
| EP-1791835-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-06-06 | — | — | EP | disclosed |
| EP-1786792-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | Astellas Pharma Inc. (JP) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006028269-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 IHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-03-16 | — | — | WO | disclosed |
| WO-2006011631-A2 | THIAZOLE DERIVATIVES HAVING VAP-1 INHIBITORY ACTIVITY | ASTELLAS PHARMA INC. (JP) | 2006-02-02 | — | — | WO | disclosed |
| US-5739376-A | Fullerene derivatives, methods of preparing them and their use | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-04-14 | — | — | US | disclosed |
| EP-0695287-B1 | FULLERENE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AG (DE) | 1997-10-29 | — | — | EP | disclosed |
| EP-0695287-A1 | FULLERENE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AG (DE) | 1996-02-07 | — | — | EP | disclosed |
| WO-1994025424-A1 | FULLERENE DERIVATIVES, METHODS OF PREPARING THEM AND THEIR USE | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015202-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | CYP4F2 1644/4885CYP4A11 3157/4885MAPT 1178/4885 |
| US-20070254931-A1 | Thiazole Derivatives Having Vap-1 Inhibitory Activity | VCAM1, VAPB, VAPA | CYP4F2 3252/4885CYP4A11 3481/4885MAPT 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.